Does Period Blood Have Stem Cells? A Surprising Discovery

Period blood does contain stem cells, and their discovery in 2007 caught many researchers off guard. These cells, formally called menstrual blood-derived stem cells (MenSCs), behave like mesenchymal stem cells and can transform into several different tissue types, from bone to nerve to heart muscle. What makes them especially interesting is how easy they are to obtain: no surgery, no bone marrow biopsy, no embryo. Just menstrual fluid, collected noninvasively from a willing donor. The science is still young, but the potential has drawn serious attention from labs around the world.

How They Were Found

Before 2007, menstrual blood was treated as biological waste. Then researchers demonstrated that the cells shed from the uterine lining during menstruation included a population with genuine stem cell properties.¹ These cells could self-renew, they could be multiplied in lab dishes, and they could be coaxed into becoming other cell types. That finding reframed something people had dismissed for centuries. The uterine lining regenerates itself every menstrual cycle, growing several millimeters of new tissue in a matter of days. In hindsight, the presence of stem cells in that tissue makes biological sense: nothing regenerates that fast without a resident population of progenitor cells driving the process.

The discovery also arrived at a politically charged moment. Embryonic stem cell research was tangled in ethical debates, and bone marrow harvesting required painful procedures. MenSCs offered a source that was accessible, renewable, and free of the controversies surrounding embryonic tissue.² That combination of scientific promise and ethical simplicity helped the field grow quickly.

What Kind of Stem Cells Are They

MenSCs are a type of adult stem cell, not embryonic. They share features with mesenchymal stem cells found in bone marrow, fat tissue, and umbilical cord blood, but they originate from the endometrium, the lining of the uterus. When scientists examine them under flow cytometry, they express the classic surface markers expected of mesenchymal stem cells (including CD73, CD105, CD29, and CD44) while lacking markers associated with blood-forming stem cells.³ That profile tells researchers the cells are stromal in nature, meaning they come from connective tissue rather than the blood itself.

There is, however, genuine inconsistency in how different labs characterize these cells. Some groups have found markers associated with pluripotency, while others testing the same markers come up empty. A 2021 review noted that controversy arises around markers like CD117 (c-KIT), which one lab used to purify MenSCs but which other groups found to be absent. Similar disagreements exist for pluripotency markers like Oct4 and NANOG.⁴ These discrepancies probably reflect differences in collection methods, culture conditions, and the point in the menstrual cycle when samples are taken. The field has not yet settled on a single standardized protocol for isolating and identifying MenSCs, which is one reason clinical translation has been slow.

What These Cells Can Become

MenSCs are considered multipotent, meaning they can become several cell types but not every cell type. In lab dishes, researchers have successfully pushed them toward bone cells, cartilage cells, fat cells, and heart muscle cells (mesodermal lineage), as well as liver-like cells (endodermal lineage) and nerve and glial cells (ectodermal lineage).⁵ That range is broader than many adult stem cell types, which tend to favor differentiation within their own tissue layer.

One study specifically demonstrated that MenSCs could be driven toward an epidermal (skin) lineage, suggesting potential for treating wounds, burns, and other dermatological conditions.³ It is worth noting, though, that differentiating in a lab dish is not the same as functioning properly inside a living body. The 2021 iScience review cautioned that better cell characterization and more robust efficiency data are still needed before these differentiation results can be considered clinically reliable.

Why Researchers Are Excited Compared to Other Stem Cell Sources

Several practical advantages set MenSCs apart from stem cells harvested through conventional methods. Collection is painless and noninvasive. A menstrual cup can capture the sample during a normal period. Most published protocols call for roughly 5 to 10 milliliters of menstrual blood, collected during the first few days of the cycle.³ The cells can be isolated from that sample using straightforward lab techniques, and at least one study showed that simply culturing the whole menstrual blood directly (without fancy separation steps) produced a high yield of cells with stem cell properties.⁶

Once isolated, MenSCs multiply fast. Head-to-head comparisons with bone marrow mesenchymal stem cells (the current gold standard for many therapies) have found that MenSCs produce two to four times as many colony-forming progenitor units and migrate more readily in lab assays.⁷ Another comparison confirmed the higher proliferation rate and noted distinct differences in how the two cell types express surface markers.⁸ Faster growth means more cells available for research or therapy from a smaller starting sample, which matters when scaling up for potential clinical use.

Supply is another underappreciated advantage. A healthy menstruating person sheds endometrial tissue roughly every month for decades. Bone marrow donation, by contrast, requires anesthesia and a needle into the hip. Umbilical cord blood can only be collected once, at birth. The renewable nature of menstrual blood makes it possible, in theory, for a person to bank their own cells repeatedly over time.

Therapeutic Research So Far

Most therapeutic work with MenSCs remains preclinical, meaning it has been tested in animals or lab models rather than in large human trials. Still, the directions are diverse and, in some cases, genuinely promising.

In reproductive medicine, MenSCs have been transplanted into the uterus of women with Asherman’s syndrome, a condition where scar tissue forms inside the uterus and thins the lining to a point where pregnancy becomes difficult. Clinical studies have reported that intrauterine transplantation of MenSCs improved endometrial thickness to above the threshold considered necessary for successful embryo implantation.⁹ For context, fertility outcomes in IVF tend to decline sharply when the uterine lining is too thin, so even modest improvements in thickness can have practical significance for patients trying to conceive.

Heart disease has also attracted attention. Early animal studies showed that transplanted menstrual blood-derived cells could integrate into damaged heart tissue in rats after an induced heart attack, reducing the size of the damaged area and improving cardiac function.¹⁰ A review of the literature concluded that the benefit comes through a combination of mechanisms: the cells release healing signals (paracrine effects), they can transform into heart muscle-like cells, and they calm harmful immune responses in the damaged tissue.¹¹

On the autoimmune front, a mouse study modeled multiple sclerosis using a standard laboratory condition called experimental autoimmune encephalomyelitis. Transplanted MenSCs reduced disease severity across multiple stages and delivery routes, performing comparably to umbilical cord-derived stem cells. The cells suppressed the overactive immune responses driving the disease, specifically tamping down the T cell populations responsible for attacking the nervous system.¹²

MenSCs have even been explored during COVID-19, with case reports examining their immunomodulatory effects on patients with severe respiratory inflammation.¹³ That work is extremely preliminary, but it illustrates the breadth of conditions researchers think these cells might eventually address.

Tissue Engineering and Organ Scaffolds

Beyond direct cell transplantation, MenSCs are being tested in the growing field of tissue engineering. In one experiment, researchers took a mouse uterus, stripped it of all its living cells (a process called decellularization) to leave behind a protein scaffold shaped like a uterus, and then seeded that scaffold with MenSCs. The stem cells attached within 24 hours and proliferated rapidly, taking on a spindle shape characteristic of structural tissue cells.¹⁴ The goal of this kind of work is to eventually build functional tissue replacements, potentially offering options for women who have lost uterine tissue to disease or surgery. We are a long way from a lab-grown uterus, but the proof-of-concept results have been encouraging.

Do Age and Cycle Timing Matter

A reasonable question for anyone considering the practical implications: do these stem cells get worse as a person ages? A study that specifically investigated the effects of donor age and the number of times cells were grown in culture found that the basic identity of MenSCs, including their surface markers and general appearance, did not change significantly with the donor’s age. However, after prolonged culture, important signaling pathways related to immune function, metabolism, and aging did shift.¹⁵ The practical takeaway is that cells collected from older donors may still look the same on the surface but behave differently under stress or after extended expansion. If menstrual blood banking ever becomes routine, this finding suggests that collecting earlier in reproductive life would give the best-quality cells, much like the logic behind cord blood banking at birth.

Timing within the menstrual cycle also matters. Most collection protocols specify the second or third day of menstruation, when the heaviest flow typically occurs and when the endometrial lining is actively shedding its richest layer of tissue.¹⁶ Collecting later in the period, when flow is lighter, may yield fewer stem cells, though this has not been extensively studied in comparative trials.

The Endometriosis Connection

Endometriosis, in which tissue resembling the uterine lining grows outside the uterus, has a complicated relationship with MenSCs. Some researchers believe that stem cells from menstrual blood may travel backward through the fallopian tubes (a phenomenon called retrograde menstruation) and implant in places they should not, contributing to the disease. This theory is supported by molecular evidence: MenSCs from women with endometriosis show distinct differences from those of healthy women, including a strong pattern of extra methylation across their genomes. One study identified over 450 regions of the genome that were hypermethylated in endometriosis-associated MenSCs.¹⁷ These epigenetic differences could help explain why some women’s menstrual stem cells are more likely to survive and proliferate in abnormal locations.

The same cellular properties that make MenSCs therapeutically appealing, their vigor, their ability to differentiate and migrate, are exactly the properties that could make them dangerous when they end up somewhere they do not belong. This dual nature is one of the more thought-provoking aspects of the whole field.

Public Awareness Is Strikingly Low

Despite nearly two decades of research, most people have no idea that menstrual blood contains stem cells. Surveys consistently show this. A study of Turkish midwifery students found that only about 8% were aware that menstrual blood contains stem cells, and fewer than 3% knew that menstrual blood banking exists.¹⁸ Among female healthcare workers in India, roughly half had adequate knowledge about MenSCs, though education level and income were significant factors in awareness.¹⁹

The cultural taboo surrounding menstruation plays an obvious role. In many societies, periods are not discussed openly, and the idea of collecting and preserving menstrual blood can provoke discomfort even among people who would happily bank cord blood or donate bone marrow. Yet when women are actually told about the science, their response tends to be positive. One study found that 78% of menstruating women were willing to donate menstrual blood after learning what it could be used for. Interestingly, women in that study also rated their experience of menstruation more positively after learning that their periods contained something medically valuable.²⁰ That is a small but genuinely heartening finding: reframing menstruation as a source of something useful could shift how people feel about a process that many dread.

Why Menstruation Exists in the First Place

Menstruation is far rarer in the animal kingdom than most people assume. Only a handful of mammalian groups menstruate, including primates, some bats, and the elephant shrew. Current evolutionary thinking holds that the key development was spontaneous decidualization, a process in which the uterine lining transforms on its own each cycle regardless of whether an embryo is present. In species that menstruate, the lining does not wait for a pregnancy signal before remodeling; it rebuilds and, if no embryo implants, sheds. One leading theory views this as a maternal defense mechanism, protecting the parent from the potentially invasive behavior of an implanting embryo by giving the mother’s body control over when the lining is receptive.²¹

This evolutionary context matters because it explains why the uterine lining is so rich in stem cells. The endometrium has to rebuild itself from scratch roughly 400 times over a person’s reproductive lifespan. That kind of regenerative demand requires a robust reservoir of progenitor cells embedded in the tissue. The stem cells that researchers discovered in 2007 were always there, doing exactly the job evolution designed them for. Science just took a surprisingly long time to look.